Original Source(s)
Related Content
FDA Approves New Oral Option for Plaque Psoriasis
Phase 3 data showed high skin clearance rates and adverse event rates similar to placebo through week 16 with once-daily icotrokinra.
March 18, 2026
-
2 min
Case Report: Repigmentation and complete hair regrowth in an 11-year-old preadolescent with alopecia totalis treated with a JAK inhibitor
by Yanhong Jia, Xue Wang, Yuanxiang Liu, Zigang Xu, Bin Zhang
July 16, 2026
The Hidden Differences Between Oral Contraceptives
National adverse-event and prescribing data suggest oral contraceptive formulations differ in reported acne, migraine, anxiety, and depression
by Henry Thomas
March 26, 2026
-
2 min